Details for New Drug Application (NDA): 072687
✉ Email this page to a colleague
NDA 072687 describes FOAMICON, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the FOAMICON profile page.
The generic ingredient in FOAMICON is aluminum hydroxide; magnesium trisilicate. There are one hundred and forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aluminum hydroxide; magnesium trisilicate profile page.
The generic ingredient in FOAMICON is aluminum hydroxide; magnesium trisilicate. There are one hundred and forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aluminum hydroxide; magnesium trisilicate profile page.
Summary for 072687
| Tradename: | FOAMICON |
| Applicant: | Novartis |
| Ingredient: | aluminum hydroxide; magnesium trisilicate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | 80MG;20MG | ||||
| Approval Date: | Jun 28, 1989 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
